STOCK TITAN

Cabaletta Bio Inc - CABA STOCK NEWS

Welcome to our dedicated news page for Cabaletta Bio (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cabaletta Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cabaletta Bio's position in the market.

Rhea-AI Summary
Cabaletta Bio, Inc. reports financial results and progress in autoimmune disease treatment trials. The company dosed the first patient with CABA-201 in the RESET clinical trial program, with initial data expected in 2024. FDA grants Rare Pediatric Disease designation for CABA-201. Cash runway into 1H26 with $241.2 million in cash and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
-
Rhea-AI Summary
Cabaletta Bio, Inc. receives Orphan Drug Designation from the FDA for CABA-201, a promising therapy for systemic sclerosis. The clinical-stage biotechnology company aims to develop curative targeted cell therapies for autoimmune diseases, focusing on B cell-driven conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
-
Rhea-AI Summary
Cabaletta Bio, Inc. (CABA) to participate in two investor conferences in March, showcasing their innovative curative targeted cell therapies for autoimmune diseases. CEO Steven Nichtberger to feature in TD Cowen 44th Annual Health Care Conference and management to attend Jefferies Biotech on the Bay Summit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
conferences
Rhea-AI Summary
Cabaletta Bio, Inc. receives Orphan Drug Designation from the FDA for CABA-201, a potential curative therapy for autoimmune diseases. The drug is designed to deplete CD19-positive B cells, aiming to provide durable remission off therapy for patients with myositis and other autoimmune diseases. The FDA designation grants Cabaletta certain incentives, including tax credits, waived user fees, and potential marketing exclusivity for seven years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.05%
Tags
-
Rhea-AI Summary
Cabaletta Bio, Inc. (Nasdaq: CABA) announced CEO participation in Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The live webcast will be available on the company's website with replays for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
conferences
-
Rhea-AI Summary
Cabaletta Bio, Inc. (Nasdaq: CABA) has received second and third FDA Fast Track Designations for CABA-201, an investigational 4-1BB-containing fully human CD19-CAR T cell therapy, for the treatment of patients with dermatomyositis and systemic sclerosis. This provides the opportunity for expedited development and review of CABA-201 for the treatment of these autoimmune diseases. CABA-201 is designed to deeply and transiently deplete CD19-positive B cells following a one-time infusion, potentially enabling an 'immune system reset' with the potential for durable remission off therapy in patients with autoimmune diseases. The company has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple autoimmune conditions and is conducting four Phase 1/2 clinical trials with a total of nine cohorts that can advance simultaneously.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
Rhea-AI Summary
Cabaletta Bio, Inc. (Nasdaq: CABA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences
-
Rhea-AI Summary
Cabaletta Bio, Inc. (Nasdaq: CABA) CEO to participate in fireside chat at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
conferences
-
Rhea-AI Summary
Cabaletta Bio, Inc. (Nasdaq: CABA) reported financial results for Q3 2023, including an update on the CABA-201 clinical trials for lupus and myositis. Initial clinical data is expected in the first half of 2024, with expanded trials into rheumatology and neurology. Cash reserves are expected to support operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
Rhea-AI Summary
Cellares and Cabaletta Bio announce collaboration to evaluate Cellares' Cell Shuttle platform for manufacturing Cabaletta's CD19-CAR T cell therapy. The collaboration aims to automate manufacturing processes and potentially deliver therapies for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
partnership
Cabaletta Bio Inc

Nasdaq:CABA

CABA Rankings

CABA Stock Data

821.55M
39.40M
3.14%
102.27%
17.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Philadelphia

About CABA

cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un